Alere Inc.: Rembrandt Diagnostics LP v. Alere, Inc. (Fed. Cir. 2023)

By Kevin E. Noonan -- The Federal Circuit reviewed the latest decision from the Patent Trial and Appeal Board (PTAB) in an inter partes review that claims 3-6 and 10 of U.S. Patent No. 6,548,019 are obvious, in Rembrandt Diagnostics LP v. Alere, Inc.; prior proceedings were reported at Alere, Inc. v. Rembrandt Diagnostics, LP, 791 F. App'x 173 (Fed. Cir. 2019), and Rembrandt Diagnostics, LP v. Alere, Inc., 809 F. App'x 903 (Fed. Cir. 2020). The claims are directed to assay devices for testing biological fluids, as illustrated in Figures 3 and 6 and explained in the opinion as...